Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)

Next Previous
Trial Profile

A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denifanstat (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms FASCINATE-2
  • Sponsors Sagimet Biosciences

Most Recent Events

  • 06 Apr 2026 According to a Sagimet Biosciences media release, data from this trial will be presented at Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada.
  • 08 Jan 2026 According to a Sagimet Biosciences media release, the anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in this trial will be presented in a poster on Saturday, January 10, 2026- at the 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah.
  • 10 Nov 2025 According to a Sagimet Biosciences media release, data from the trial presented at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2025, taking place November 7-11, 2025 in Washington, DC.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top